TY - JOUR
T1 - Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
AU - Yoest, Jennifer M.
AU - Shirai, Cara Lunn
AU - Duncavage, Eric J.
N1 - Publisher Copyright:
© Copyright © 2020 Yoest, Shirai and Duncavage.
PY - 2020/5/8
Y1 - 2020/5/8
N2 - Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.
AB - Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.
KW - AML MRD
KW - acute myeloid leukemia
KW - clinical applications of NGS
KW - error-corrected sequencing
KW - measurable (minimal) residual disease
KW - next generation sequencing
KW - unique molecular identifier
UR - http://www.scopus.com/inward/record.url?scp=85085065961&partnerID=8YFLogxK
U2 - 10.3389/fcell.2020.00249
DO - 10.3389/fcell.2020.00249
M3 - Review article
C2 - 32457898
AN - SCOPUS:85085065961
SN - 2296-634X
VL - 8
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
M1 - 249
ER -